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Objective. Whole-exome sequencing (WES) studies
in systemic sclerosis (SSc) patients of European American
(EA) ancestry have identified variants in the ATP8B4 gene
and enrichment of variants in genes in the extracellular
matrix (ECM)–related pathway that increase SSc suscep-
tibility. This study was undertaken to evaluate the associa-
tion of the ATP8B4 gene and the ECM-related pathway
with SSc in a cohort of African American (AA) patients.
Methods. SSc patients of AA ancestry were enrolled
from 23 academic centers across the US under the Genome
Research in African American Scleroderma Patients con-
sortium. Unrelated AA individuals without serologic evi-
dence of autoimmunity who were enrolled in the Howard
University Family Study were used as unaffected controls.
Functional variants in genes reported in the 2 WES studies
in EA patients with SSc were selected for gene association
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testing using the optimized sequence kernel association test
(SKAT-O) and pathway analysis by Ingenuity Pathway
Analysis in 379 patients and 411 controls.
Results. Principal components analysis demon-
strated that the patients and controls had similar ances-
tral backgrounds, with roughly equal proportions of mean
European admixture. Using SKAT-O, we examined the
association of individual genes that were previously re-
ported in EA patients and none remained significant,
including ATP8B4 (P = 0.98). However, we confirmed the
previously reported association of the ECM-related path-
way with enrichment of variants within the COL13A1,
COL18A1, COL22A1, COL4A3, COL4A4, COL5A2, PROK1,
and SERPINE1 genes (corrected P = 1.953 104).
Conclusion. In the largest genetic study in AA
patients with SSc to date, our findings corroborate the role
of functional variants that aggregate in a fibrotic pathway
and increase SSc susceptibility.
Systemic sclerosis (SSc; scleroderma) is a chronic
multisystem disease, characterized by fibrosis of the skin
and internal organs, systemic vasculopathy, and autoimmu-
nity. Compared with individuals of European American
(EA) ancestry, African Americans (AA) in the US have a
higher incidence and prevalence of SSc (1). SSc occurs at
an earlier age in persons of AA descent compared to EA
and is more likely to be manifested as diffuse skin involve-
ment and the presence of anti–topoisomerase I or
antifibrillarin antibodies—features that are associated with
severe disease and a worse outcome (2). AA individuals
are more likely to develop severe interstitial lung disease
(ILD) or pulmonary arterial hypertension. This lung dis-
ease accounts for the major overall SSc-related deaths in
all racial groups (3).
The etiology of SSc is unknown, but several environ-
mental agents and genetic variants have been implicated. A
strong role of genetic etiologic factors has been suggested
by family studies in SSc, which have demonstrated an abso-
lute risk of 1.6% in families as compared to 0.026% in the
general population (4). Candidate gene, family-based, and
genome-wide association studies (GWAS) investigating
common variants, that have been conducted mostly in EA
patients with SSc, have revealed autoimmune disease sus-
ceptibility loci that are not unique to SSc (5). These studies
focused on common variants that have been able to only
partially account for SSc heritability. Rare variants (minor
allele frequency [MAF] <0.5%) and low-frequency variants
(MAF 0.5–5%) have recently been implicated in several
diseases and could account for a portion of the missing data
on SSc heritability.
Recent reports suggest an increased burden of rare
coding variants in genes and pathways of complex diseases
beyond the common variants identified by GWAS (6,7).
Various techniques used to identify genes with aggrega-
tion of deleterious variants include candidate gene Sanger
sequencing for a hypothesis-driven approach. Next gen-
eration sequencing platforms, including whole-exome
sequencing (WES) and whole-genome sequencing, pro-
vide hypothesis-neutral approaches. Gao et al (6) recently
performed WES in 78 EA patients with SSc and found an
enrichment in functional ATP8B4 variants as compared to
controls (P = 2.77 9 10–7). Furthermore, a single missense
variant (rs55687265) was associated with SSc (P = 9.35 9
10–10), and when this variant was removed, the ATP8B4
gene–based association was eliminated. Mak et al (7) per-
formed WES in 32 EA patients with SSc, identifying 70
genes enriched for deleterious variants in the diffuse SSc
subset; they reported significant enrichment of variants
in the COL4A3, COL4A4, COL5A2, COL13A1, and
COL22A1 genes in the extracellular matrix (ECM)–
related pathway (P = 0.002). Given the potential impor-
tance of the findings of these prior smaller WES studies
in EA patients with SSc, we investigated their significance
in a larger cohort of AA patients with SSc by performing
WES gene and pathway-based association testing.
Our understanding of genetic susceptibility in AA
patients with SSc is limited and restricted to HLA anti-
gens, due to the lack of extensive studies in the AA pop-
ulation (8). The Genome Research in African American
Scleroderma Patients (GRASP) consortium was created
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to assemble a large cohort of AA patients with SSc in
order to conduct systematic and comprehensive genetic
studies. Within the cohort, 400 AA patients with SSc
and 482 controls have undergone WES, and studies of
select genes from the WES analysis are being replicated
in an independent series for confirmation. Herein we
present the results of our analyses for gene-level associa-
tions and pathway associations in genes that were previ-
ously reported in WES studies of 76 EA patients with
SSc by Gao et al and 32 EA patients with SSc by Mak
et al (6,7). We replicated a collective enrichment of cod-
ing and deleterious variants in genes of the fibrotic path-
way in AA patients with SSc.
PATIENTS AND METHODS
Study population. AA patients with SSc were enrolled in
the GRASP consortium from 23 academic centers in the US (see
Supplementary Table 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40541/
abstract). Enrolled patients self-identified as African American.
All patients met the 1980 American College of Rheumatology
(ACR) or the 2013 ACR/European League Against Rheumatism
classification criteria for SSc (9,10) or had at least 3 of the 5 fea-
tures of CREST syndrome (calcinosis, Raynaud’s phenomenon,
esophageal dysmotility, sclerodactyly, telangiectasias) (11). Con-
trol samples were obtained from the Howard University Family
Study, a population-based study of AA families and unrelated
individuals enrolled in the Washington, DC metropolitan area
(12). Only unrelated individuals were included as controls. Sera
obtained from controls were tested for antinuclear antibodies
(ANAs) by indirect immunofluorescence, and only those with a
titer of <1:80 were included in this study. DNA was extracted
from samples of whole blood or saliva.
Sequence analysis. WES was performed on 400 SSc
and 482 control samples using SeqCap EZ Human Exome +
UTR Probes (Roche), and libraries were sequenced on the
HiSeq 2000 platform (Illumina) using 2 9 100-bp paired-end
reads. WES data were analyzed using the computational
resources of the NIH high-performance computing Biowulf
cluster (http://hpc.nih.gov). Multiple variant and sample quality
control filters were used prior to analyses (see Supplementary
Methods, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.40541). The
sequence data shown in this study are accessible from the
Sequence Read Archive under the accession number SRP140756.
Identity by descent, admixture, and principal compo-
nents analyses. Identity by descent analysis was performed using
common variants (MAF >5%) from the sequence data after
linkage disequilibrium (LD) pruning (r2 <0.5) for estimating kin-
ship coefficients. In order to remove familial relatedness, only 1
sample with the highest call rate was included from individuals
with pi-hat >0.085. We used the ADMIXTURE software tool
(13) and the 1000 Genomes populations as references for esti-
mation of population admixture in our patients and controls.
Principal components analysis (PCA) was used to estimate
population stratification. A set of 35,280 markers (LD pruned
[r2 <0.5] and MAF >5%) was used to compute principal compo-
nents and the top ten principal component eigenvalues were
used to correct for population stratification using SNP & Varia-
tion Suite v8.7.1 (Golden Helix). Samples that clustered within
the European cluster were removed from the analysis.
Statistical analysis. Gene-level testing was performed
using an optimized sequence kernel association test (SKAT-O)
with Madsen and Browning marker weighting and was corrected
for ancestry using the top 10 principal components. Functional
variants (missense, nonsense, and splice site) with a MAF of
<0.05 present on 20 candidate genes as reported by Gao et al
(6), and functional variants of all frequencies present on 87
genes from the diffuse disease and ILD subsets of SSc patients
analyzed by Mak et al (7) were examined for association in the
GRASP cohort (see Supplementary Figure 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40541/abstract). In order to account for
multiple gene testing, Bonferroni correction was applied for the
total number of tests performed. This included 20 tests for the
Gao et al study and 87 for the Mak et al study, which yielded
P value significance thresholds of 0.0025 and 0.00057, respec-
tively (6,7). Ingenuity Pathway Analysis (IPA) software was used
to identify canonical pathways with all of the reported genes in
the studies by Gao and colleagues and Mak and colleagues.
P values for pathways were generated using Fisher’s right-tailed
exact test and were corrected for multiple testing using the
Benjamini-Hochberg false discovery rate criterion.
RESULTS
Patient characteristics. A few controls (2.17%)
were ANA+ (titer ≥1:80) and were excluded from the
study. As we had hypothesized, there were more female
subjects in the SSc cohort as compared to the control
cohort (Table 1). Detailed sociodemographic, clinical, and
serologic characteristics of the GRASP cohort have been
reported by Morgan et al (11). In order to address popula-
tion stratification, we performed PCA and plots showed
that the patients and controls in the GRASP cohort were
well-matched and that there was no major stratification at
a global genomic level (Figure 1 and Supplementary
Table 1. Clinical and serologic characteristics of the African American





Sex, male/female 64 (16.9)/315 (83.1) 217 (52.8)/194 (47.2)
SSc skin involvement
Limited 166 (43.8) –
Diffuse 188 (49.6) –
Autoantibodies
Anticentromere 44 (11.6) –




Interstitial lung disease 114 (30.1)‡ –
* Values are the number (%) of patients with systemic sclerosis (SSc)
and unaffected controls.
† Data are based on right-sided heart catheterization.
‡ Data are based on computed tomography of the chest.
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Figures 2 and 3, available at http://online.library.wiley.
com/doi/10.1002/art.40541/abstract).
Results of sequence analysis. A total of 400 SSc
and 482 control exomes were sequenced using the same
platform and were analyzed simultaneously. After
filtration for quality control, 379 SSc cases and 411 con-
trols remained and were used for further analysis (see
Supplementary Methods, available at http://online.library.
wiley.com/doi/10.1002/art.40541/abstract). An average of
90% of targeted bases produced high-confidence calls,
and mean depth of coverage was 479 in the targeted
region. The transition-to-transversion ratio for the coding
region was 3.29, and the ratio for heterozygous-to-
nonreference homozygous variants was 2.6.
PCA was performed for fine characterization of
genetic ancestry. A 3-dimensional PCA plot depicted the
AA patients to be spread between the West African and
European clusters based on their degree of European
admixture (Figures 1A and B, and Supplementary Fig-
ures 2 and 3, http://online.library.wiley.com/doi/10.1002/
art.40541/abstract). The GRASP samples were closer to
the West African cluster and distinct from the East Afri-
can cluster, confirming West Africa as the main ancestral
home of the AA patients. The admixture proportions in
GRASP samples were similar to those in AA persons in
the 1000 Genomes Project (Americans of African Ances-
try in southwestern US), with major contributions from
West African and European ancestries and a minor
Figure 1. A and B, Three-dimensional principal components analysis (PCA) plots of the 1000 Genomes populations (A) and the 1000 Genomes
populations along with the systemic sclerosis (SSc) patients and controls from the present study (B). Each dot represents an individual subject.
Patients with SSc (red), controls (blue), Americans of admixture (Colombians from Medellin, Colombia [CLM], subjects of Mexican Ancestry from
Los Angeles, California [MXL], and Puerto Ricans from Puerto Rico [PUR]) (gold), African Americans (light blue), East Africans (Luhya in
Webuye, Kenya [LWK]) (orange), East Asians (Han Chinese in Beijing [CHB], Southern Han Chinese [CHS], and Japanese in Tokyo, Japan
[JPT]) (purple), Europeans (Utah Residents of North and Western Europe ancestry [CEU], Finnish in Finland [FIN], British in England and Scot-
land [GBR], Iberian population in Spain [IBS], and Toscani in Italy [TSI]) (black), and West Africans (Yoruba in Ibadan, Nigeria [YRI]) (light
green) are shown. C, Admixture plot of the 1000 Genomes populations along with the SSc patients and controls from the present study. Each indi-
vidual subject is represented as a vertical bar. The y-axis depicts contributions from African (green), European (blue), Asian (red), and Hispanic
ancestries. The results in cases and controls are similar to each other and similar to those in the Americans of African Ancestry in southwestern
US (ASW) group from the 1000 Genomes project. D, Three-dimensional PCA with the top 3 principal components. Each dot represents an indi-
vidual subject. Patients with SSc (red) and controls (blue) are shown.
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contribution from Asian ancestry, likely representing
Native American admixture (Figure 1C). The mean 
SD individual European admixture was 16.98  12.4%
in the SSc samples and 16.52  11.7% in controls, and
the difference was not statistically significant (P = 0.59,
by t-test) (see Supplementary Figure 4, available at http://
online.library.wiley.com/doi/10.1002/art.40541/abstract).
The PCA plot also confirmed that the patients and
controls were very ancestrally similar to each other
(Figure 1D).
Gene-level analysis. All variants in the 20 genes, as
described in the report by Gao and colleagues (6), were
included for gene-level testing by SKAT-O with the top 10
principal components as covariates. The ATP8B4 gene-level
association reported in EA patients did not reach statistical
significance in the GRASP cohort (P = 0.98) (see Supple-
mentary Tables 2 and 3, available at http://online.library.
wiley.com/doi/10.1002/art.40541/abstract). A missense vari-
ant (rs55687265), which was found to be the primary signal
for association in the ATP8B4 gene in the study by Gao
et al (6), had similar frequency in the SSc patients and con-
trols and was not statistically significant in the GRASP
cohort (P = 0.84) (Supplementary Table 4, http://online.
library.wiley.com/doi/10.1002/art.40541/abstract).
The 87 unique genes that were identified in the
study by Mak and colleagues (7) were evaluated in the
GRASP cohort by SKAT-O. For the COL4A4 gene,
the P value was 0.038, but this did not remain significant
after correction for multiple testing (see Supplementary
Table 5, available at http://online.library.wiley.com/doi/10.
1002/art.40541/abstract). Upon examining the subset of SSc
patients with diffuse disease, we discovered the MSR1 gene
(P = 0.01), and when evaluating the subset of SSc patients
with ILD we identified the ZNF492 gene (P = 0.01), the
FOLR3 gene (P = 0.03), and the STAB1 gene (P = 0.04).
After correction for multiple testing, however, these associa-
tions were not statistically significant (see Supplementary
Tables 6 and 7, available at http://online.library.wiley.com/
doi/10.1002/art.40541/abstract). The growth differentiation
factor 2 gene (GDF-2) was reported by Mak et al to have a
potential enrichment of variants by burden ratio (7) and was
significant with an uncorrected P value of 0.00029 in the
study by Gao et al (6). In the GRASP cohort this gene ini-
tially showed significance (uncorrected P = 0.04), but it did
not remain significant after correction for multiple testing
(see Supplementary Table 2, available at http://online.library.
wiley.com/doi/10.1002/art.40541/abstract).
Pathway-based analysis. IPA was used to predict
pathways enriched with gene variants. Gene-level associa-
tion results from the SKAT-O analysis of the 20 genes
from the study by Gao et al and the 87 genes from the
study by Mak et al (6,7), in all SSc patients, were used for
pathway prediction. None of the pathways that were pre-
dicted based on the gene list from the study by Gao and
colleagues were statistically significant after correction for
multiple testing. The hepatic fibrosis/hepatic stellate cell
activation pathway, identified with IPA based on the gene
list in the study by Mak and colleagues, comprised not
only the COL13A1, COL22A1, COL4A3, COL4A4, and
COL5A2 genes, but additionally included the COL18A1,
PROK1, and SERPINE1 genes belonging to the same
pathway (see Supplementary Table 8, available at http://
online.library.wiley.com/doi/10.1002/art.40541/abstract).
In the GRASP cohort, this was the only pathway that was
statistically significant after correction for multiple testing
(corrected P = 1.95 9 10–4) (Table 2). After correction
for multiple testing, the hepatic fibrosis/hepatic stellate
cell activation pathway was the only significant pathway in
the subset of SSc patients with diffuse disease (Table 2).
DISCUSSION
In this large cohort of AA patients with SSc, we
examined the 20 candidate genes as identified by Gao
et al and the 87 candidate genes as identified by Mak
et al in their recent WES studies of EA patients with SSc
(6,7). Despite having a much larger sample size than these
original studies, we were unable to replicate the ATP8B4
gene association or the rs55687265 variant in the ATP8B4
gene in the present study. We were, however, able to
replicate the association with the ECM-related pathway,
but found no additional associations.
Table 2. Pathway analysis of the candidate genes in the GRASP cohort*
Ingenuity pathway P† Corrected P‡
All SSc patients versus controls
Hepatic fibrosis/hepatic stellate
cell activation
2.09 9 10–6 1.95 9 10–4
Melatonin degradation III 0.005 0.22
Coagulation system 0.01 0.29
Complement system 0.01 0.29
Atherosclerosis signaling 0.02 0.34




2.27 9 10–6 2.14 9 10–4
Melatonin degradation III 0.005 0.22
Coagulation system 0.01 0.29
Complement system 0.01 0.29
Atherosclerosis signaling 0.02 0.36
* Data depict the top 5 pathways and results from the optimized se-
quence kernel association test of the 87 genes (from the study by Mak
et al [7]) in all patients with systemic sclerosis (SSc) and in the diffuse
SSc patient subset. The Ingenuity Pathway Analysis program was used
for predicting pathways. GRASP = Genome Research in African Ameri-
can Scleroderma Patients.
† By Fisher’s right-tailed exact test.
‡ Corrected for multiple testing using the Benjamini-Hochberg
correction.
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One of the greatest accomplishments achieved as
a result of this investigation is the establishment of the
GRASP cohort, which comprised a large sample of AA
patients with SSc and controls with similar ancestral back-
grounds. The GRASP cohort will serve as a valuable
resource for future transethnic genomic studies in SSc.
Based on the genes reported as candidates for asso-
ciation in the study by Mak et al (7), pathway analysis in
the GRASP cohort highlighted a fibrotic pathway that had
enrichment of genes with functional variants involved in
ECM biology. The gene list included several genes in the
collagen family and genes involved in fibrinolysis and
angiogenesis. The clustering of these genes into a fibrosis
network corresponds to the excessive synthesis and deposi-
tion of ECM proteins observed in SSc and, thus, could be
a potential candidate for targeted therapy. The GDF2
gene (also known as bone morphogenetic protein 9) that
was evaluated in the present study and identified in the
studies by Gao et al and Mak et al (6,7) did not reach sta-
tistical significance after correction for multiple testing,
but remains an interesting candidate gene involved in
modulation of the ECM.
In the GRASP cohort, the ancestries of AA pa-
tients as well as the controls were primarily derived from
West Africa, and on average the AA patients and controls
had similar proportions of African, European, and Asian
(likely Native American) descent. The patients and con-
trols were recruited from different geographic locations in
the US and, using PCA and the ADMIXTURE software
tool, we were able to demonstrate that there was no major
population stratification between the patients and controls.
Ancestry-specific associations have previously been
identified in complex diseases. Similar to the PADI4 gene
association in Asians and the PTPN22 gene association in
Europeans with rheumatoid arthritis, it may be the case
that there are differences in SSc susceptibility loci in dif-
ferent ancestral populations (14). The admixture of the
AA population is a recent event in human admixture his-
tory and, as we have demonstrated, contains varying
amounts of European and Asian ancestries. This differ-
ence in genetic architecture could explain the lack of asso-
ciation of the ATP8B4 gene and the rs55687265 variant in
AA patients with SSc.
In the original report of the association of the
rs55687265 variant with scleroderma in EA patients by Gao
and colleagues (6), the discovery set contained 78 patients
in whom the likelihood of association was significant (odds
ratio [OR] 6.11, P = 9.35910–10) and the replication set had
415 patients in whom a significant association was found
(OR 1.86, P = 0.01). Nevertheless, a recent study of 7,426
SSc patients and 13,087 controls of European ancestry was
also unable to replicate the association with the rs55687265
variant (15). This underscores the importance of replication
in genetics studies in large well-established cohorts to
demonstrate reproducibility, provide a better estimate of
effect size, and confirm that the original association is not
due to unidentified biases present in a single study. We
expect that, upon completion of the GRASP targeted rese-
quencing and final analysis of ~400 genes, at least a few of
these genes will show a statistically significant association
with scleroderma and increase our understanding of molec-
ular pathways involved in SSc pathogenesis.
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